Acquisitions · Cell therapy
Astellas buys Seattle cell therapy company Universal Cells for up to $102.5 million
- Buyer
- Astellas Pharma (Tokyo)
- Target
- Universal Cells, Seattle, Washington
- Value
- Up to $102.5M (upfront plus milestones)
- Status
- Completed in February 2018.
- Date
- 2018-02-13
Astellas Pharma acquired all of Universal Cells, a Seattle company developing technology for cell therapies. The price was up to $102.5 million, made up of an upfront payment and milestone payments.
Why it matters
The purchase added US cell therapy technology to Astellas as it built up its research in regenerative medicine.
Sources
Kakehashi M&A News home
